Notably, the levels of dystrophin observed after CRIPSR/Cas9 treatment are similar to those reported in human DMD patients treated with the FDA-approved exon-skipping drug eteplirsen (i.e., treated patients expressed 0.93% dystrophin relative to healthy controls).18 The gene discussed is DMD; the disease is Duchenne muscular dystrophy.